Industry news

Pharma's giants, new and old, tell more tales than their numbers show

Tracy Staton / FiercePharma

It takes some mighty big forces to shift the enormous drugmakers that, like boulders in a stream, help define the course of the pharma industry. The last 10 years of upheaval have shifted them, all right—but some moved far more than others, and there's a story behind all of them.

The 2017 report card so far: Big Biotech largely trading up as pharma posts mixed results

Eric Sagonowsky / FiercePharma

Biopharma's largest companies have faced a tumultuous year. Amid pricing pushback, payer maneuvering, biosim threats, manufacturing setbacks and other challenges, analysts with Mizuho calculated which drugmakers have managed to succeed on the stock markets this year—and which companies have struggled.

Dealmaking in 2017: Striking a Balance

Julian Upton / Pharmaceutical Executive

inVentiv Health Consulting’s Neel Patel tells Pharm Exec that biopharma dealmaking in 2017 is robust and generally immune to external pressures in the short term—but the art of the deal is still being compromised by factors under the buyer and seller’s control.

Stanford University and Takeda will collaborate on drug discovery

GMP News

A new partnership between Stanford University and one of the world’s oldest and largest drug makers, Takeda Pharmaceutical Company Ltd., could help speed up the process of bringing drugs from discovery to market.

Teva has long-term plans for the Russian market

GMP News

In its financial report for Q2 2017, Teva announced that it was curtailing the activities in 45 countries. The Russian office continues to operate as usual, without any changes in its operating activities. The company is successfully developing the local manufacturing at its plant in Yaroslavl and has long-term plans for the Russian market, which remains a strategic one for Teva.

10 August 2017

Syndax Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Clinical and Business Update

Syndax Pharmaceuticals, Inc.  ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today reported its financial results for the second quarter ended  June 30, 2017 . In addition, the Company provided a clinical and business update. As of  June 30, 2017 , Syndax had  $130.0 million  in cash, cash equivalents and short-term investments.

10 August 2017

Neothetics Provides Business Update and Reports Second Quarter 2017 Financial Results

Neothetics , Inc. (NASDAQ:NEOT) provided a business update and reported financial results for the second quarter 2017.

What do kids think of their parents' RA? Amgen's new Enbrel push offers a few ideas

Beth Snyder Bulik / FiercePharmaMarketing

In Amgen’s latest campaign for Enbrel, kids are speaking up. Two new TV commercials feature children talking about their parents’ painful arthritis and their worries about it. The “Being There” campaign includes one TV ad focused on a mother, and another on a father. The TV ads began running last week, backed by combined spending of just under $2 million so far, according to data from real-time TV tracker iSpot.tv.

Pfizer commits $100M for a gene therapies plant in North Carolina

Eric Palmer / FiercePharma

Pfizer committed to building a $100 million gene therapies plant in North Carolina and in exchange, North Carolina committed to providing the drugmaker with a quarter-million dollars' worth of help.

09 August 2017

Clearside Biomedical, Inc. Announces Second Quarter 2017 Financial Results and Provides Corporate Update

Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today reported financial results for the quarter and six months ended June 30, 2017 and provided an update on its development programs.